Cold Plasma Technology Is Emerging as a Cross-Sector Industrial Platform Addressing Sterilisation, Surface Activation, Wound Decontamination, and Food Pathogen Reduction Across Healthcare, Electronics, and Agri-Food Processing

Cold plasma technology, which generates a partially ionised gas at near-ambient temperatures through electrical discharge, is demonstrating a range of industrial utility that makes it one of the more genuinely novel process technology platforms to emerge from laboratory research toward broad commercial application in the past decade. Unlike high-temperature plasma used in semiconductor manufacturing and metal cutting, cold plasma or non-equilibrium plasma operates at temperatures compatible with biological tissues, food products, and polymer substrates, enabling decontamination, surface modification, and chemical activation without thermal damage. The convergence of declining equipment costs, expanding published application evidence, and growing regulatory acceptance is moving cold plasma from niche research installations toward viable commercial deployment across healthcare sterilisation, electronics manufacturing surface treatment, food safety processing, and wound care management.

Healthcare Sterilisation and Medical Device Decontamination

Sterilisation of medical devices and healthcare facility surfaces represents the most commercially advanced cold plasma application. Cold plasma systems cleared or under regulatory review by the FDA and European Notified Bodies demonstrate broad-spectrum antimicrobial efficacy against bacteria, viruses, fungi, and endospores, including drug-resistant organisms that have become a significant infection control challenge in healthcare settings. The mechanism of antimicrobial action, primarily through reactive oxygen and nitrogen species generated in the plasma discharge, is fundamentally different from chemical disinfectants and from UV irradiation, which means cold plasma does not share the resistance development mechanisms that have compromised antibiotic and disinfectant efficacy.

The compatibility of cold plasma with complex medical device geometries that are difficult to sterilise with ethylene oxide or steam autoclaving is a significant technical advantage. Lumened devices, devices with delicate polymer or electronic components that cannot withstand steam temperatures, and implants with complex surface topography can be exposed to cold plasma without the material degradation risks associated with high-temperature or harsh chemical sterilisation methods. Hospital central sterile services departments are evaluating cold plasma systems as a complement to or replacement for some ethylene oxide sterilisation applications, particularly as EO regulatory pressure mounts due to occupational exposure and community air quality concerns.

Electronics Manufacturing Surface Activation

Atmospheric pressure cold plasma treatment is an established surface preparation technology in electronics manufacturing, used to activate and clean polymer substrate surfaces before adhesive bonding, coating application, and printing processes. Cold plasma treatment removes organic contamination and increases surface energy by introducing oxygen-containing functional groups onto polymer surfaces, dramatically improving adhesion without solvent cleaning or abrasive surface preparation steps that add waste and process complexity. Printed circuit board manufacturers, flexible electronics producers, and automotive electronic assembly operations use atmospheric plasma treatment systems as inline process steps integrated with conveyor production lines.

The demand for cold plasma surface treatment in electronics is growing alongside the expansion of advanced packaging in semiconductors, where heterogeneous integration of chiplets and advanced substrate bonding require pristine surface preparation standards. Plasma treatment systems from companies including Plasmatreat, Tantec, and Hennecke are standard process equipment in electronics assembly operations, and the expanding performance requirements of next-generation packaging are driving demand for higher uniformity and more precisely controlled surface activation outcomes than older plasma treatment system generations can achieve.

Food Safety and Agricultural Decontamination Applications

Food pathogen reduction is an emerging application area where cold plasma treatment demonstrates efficacy against Salmonella, E. coli, Listeria, and other food safety organisms on fresh produce surfaces, packaging materials, and processing equipment without introducing thermal damage to heat-sensitive food products. The absence of chemical residues from cold plasma treatment is a significant advantage over chlorine washing and other chemical decontamination approaches, particularly for organic produce markets and export markets with strict chemical residue limits. Cold plasma treatment of grain seeds and dried spices has demonstrated efficacy in reducing fungal contamination and aflatoxin levels without the fumigant chemical exposure concerns associated with methyl bromide and other conventional grain decontamination approaches.

Plasma-activated water, produced by exposing liquid water to cold plasma discharge, is demonstrating antimicrobial properties that allow it to be used as a decontamination rinse that retains activity for a period following plasma treatment. This enables centralised plasma activation of large water volumes for distribution to multiple decontamination points in food processing facilities, improving the practicality of cold plasma treatment at production scale compared to configurations requiring direct plasma exposure of food product streams. Research programmes at agricultural universities and food science institutes across Europe, North America, and Asia are actively investigating cold plasma and plasma-activated water applications, and the volume of published evidence supporting food safety efficacy continues to grow.

Wound Care and Clinical Dermatology Applications

Cold plasma wound care devices represent one of the most clinically differentiated application areas, with commercial plasma devices including the kINPen from neoplas tools and the Plasma Care device from terraplasma medical receiving CE marking for wound decontamination and dermatological treatment indications. Clinical evidence supports the efficacy of cold plasma in reducing wound bioburden, promoting wound closure in chronic wounds including diabetic foot ulcers and venous leg ulcers, and treating superficial skin infections including acne and dermatophyte conditions. The dual mechanism of direct antimicrobial activity combined with stimulation of tissue regeneration processes through reactive species signalling provides a clinical rationale that is not available from antibiotic or conventional antiseptic approaches.

Regulatory progress has been faster in Europe, where the CE marking framework has accommodated plasma wound care devices within the medical device directive pathway, than in the United States, where FDA regulatory classification for novel wound care plasma devices remains under evaluation. The resolution of US regulatory pathway uncertainty is a key catalyst for commercial scale in the North American wound care market, which represents a substantial addressable opportunity given the prevalence of chronic wound management in the ageing US population and the high cost burden of chronic wound treatment in healthcare systems.

Commercialisation Pathways and Market Development Challenges

Cold plasma technology faces the characteristic commercialisation challenges of a platform technology with demonstrated laboratory efficacy but fragmented commercial deployment across multiple application markets. Equipment cost, process integration complexity, and customer unfamiliarity with plasma physics create adoption friction in each vertical market independently, requiring sector-specific application development, regulatory pathway navigation, and market education investment simultaneously. This multi-front demand development requirement is capital-intensive and exceeds the resources of most pure-play plasma companies, creating a commercialisation bottleneck that is more significant than the underlying technology limitations.

The most successful cold plasma commercialisation examples to date have typically involved established industrial equipment companies or medical device groups that have acquired or deeply partnered with plasma technology specialists and applied their distribution network, regulatory expertise, and manufacturing scale to target specific application opportunities. Plasmatreat’s success in electronics surface treatment commercialisation reflects this pattern: the company has focused commercial development on a defined application category where customer value proposition is clear, plasma treatment is a compatible process step in existing production line configurations, and the sales and support infrastructure of an established industrial equipment company can be applied effectively. The lesson for broader cold plasma market development is that segmented focus with deep application expertise and established sales infrastructure access is more commercially effective than broad platform market development from an early-stage company position. As the evidence base for food safety and wound care applications matures over the next three to five years, the conditions for similar focused commercial scale-up in those segments will become more favourable.

Top 10 Companies in Cold Plasma Technology and Non-Thermal Processing

1. Plasmatreat -- German atmospheric pressure plasma technology company providing Openair-Plasma surface treatment systems for electronics, automotive, and packaging manufacturing applications globally.
2. neoplas tools -- Developer of the kINPen cold plasma handpiece system cleared for wound decontamination and dermatology applications, with clinical research collaborations across European hospital networks.
3. terraplasma medical -- Clinical cold plasma device developer producing the Plasma Care device for chronic wound management, with CE marking and active clinical deployment in European wound care centres.
4. EP Technologies -- Provider of atmospheric plasma systems for food decontamination, seed treatment, and agricultural surface sanitisation, with installations in food processing facilities in Europe and Asia.
5. Tantec -- Danish plasma surface treatment equipment manufacturer serving electronics, medical device, and packaging manufacturing sectors with plasma treatment systems designed for inline production integration.
6. Bovie Medical -- US surgical instrument company with cold plasma portfolio including J-Plasma system for surgical tissue dissection and coagulation using helium plasma energy in minimally invasive procedures.
7. APJet -- US developer of atmospheric pressure plasma jet technology targeting medical, agricultural, and industrial decontamination applications with scalable array plasma delivery systems.
8. Hennecke -- German industrial process equipment company with plasma pre-treatment systems for composites, foams, and polymer substrates in automotive and construction material manufacturing.
9. Advanced Plasma Solutions -- Specialised plasma system integrator for food safety, packaging sterilisation, and agriculture applications with custom plasma reactor design and process engineering services.
10. Surface Technology -- UK coating and surface treatment company offering plasma cleaning, plasma nitriding, and plasma-enhanced CVD services for precision engineering and medical device manufacturing customers.